Nitric oxide signaling gone awry: Nitration of glutamine synthetase and hyperammonemia in sepsis
Aimee Landar, Victor M. Darley‐Usmar – 19 April 2005
Homocysteine, the bad thiol
José M. Mato, Shelly C. Lu – 19 April 2005
A key role for autoreactive B cells in the breakdown of T‐cell tolerance to pyruvate dehydrogenase complex in the mouse
Amanda J. Robe, John A. Kirby, David E. J. Jones, Jeremy M. Palmer – 19 April 2005 – The key immunological event in the pathogenesis of the autoimmune liver disease primary biliary cirrhosis is breakdown of T‐cell self‐tolerance to pyruvate dehydrogenase complex (PDC). The mechanism resulting in this breakdown of tolerance remains unclear.
Peginterferon alfa‐2b plus ribavirin treatment in children and adolescents with chronic hepatitis C
Stefan Wirth, Heidrun Pieper‐Boustani, Thomas Lang, Antje Ballauff, Ulrike Kullmer, Patrick Gerner, Philip Wintermeyer, Andreas Jenke – 19 April 2005 – Peginterferon plus ribavirin is standard therapy for adults with chronic hepatitis C. As no data are available for children, the aim of the study was to evaluate the efficacy and tolerability of peginterferon alfa‐2b in combination with ribavirin in chronically infected children. Genotypes, alanine aminotransferase levels, and different routes of viral transmission were considered.
Mild chronic hepatitis C with steatosis: Which treatment?
Emanuele Durante‐Mangoni, Rosa Zampino, Giuseppe Ruggiero, Luigi E. Adinolfi – 19 April 2005
Cellular responses in experimental liver injury: Possible cellular origins of regenerative stem‐like progenitor cells
William B. Coleman, D. Hunter Best – 19 April 2005
Prevalence and etiology of altered liver tests: A population‐based survey in a Mediterranean town
Gaspare Maria Pendino, Andrea Mariano, Pasquale Surace, Carmelo Antonio Caserta, Maria Teresa Fiorillo, Angela Amante, Stefania Bruno, Carmelo Mangano, Irene Polito, Fulvia Amato, Rodolfo Cotichini, Tommaso Stroffolini, Alfonso Mele, ACE Collaborating Group – 19 April 2005 – Serum biochemical liver tests (LTs) (ALT, AST, GGT) and platelet counts are often used to screen for chronic liver disease. Population‐based data on abnormal LTs in Mediterranean areas are lacking.
Inflammation and drug hepatotoxicity: Aggravation of injury or clean‐up mission?
Hartmut Jaeschke, Cathleen Cover, Mary Lynn Bajt – 19 April 2005
HIV coinfection shortens the survival of patients with hepatitis C virus‐related decompensated cirrhosis
Juan A. Pineda, Manuel Romero‐Gómez, Fernando Díaz‐García, José A. Girón‐González, José L. Montero, Julián Torre‐Cisneros, Raúl J. Andrade, Mercedes González‐Serrano, José Aguilar, Manuela Aguilar‐Guisado, José M. Navarro, Javier Salmerón, Francisco J. Caballero‐Granado, José A. García‐García – 30 March 2005 – The impact of human immunodeficiency virus (HIV) coinfection on the survival of patients with hepatitis C virus (HCV)‐related end‐stage liver disease (ESLD) is unknown.
Mechanisms of benzarone and benzbromarone‐induced hepatic toxicity
Priska Kaufmann, Michael Török, Anya Hänni, Paul Roberts, Rodolfo Gasser, Stephan Krähenbühl – 29 March 2005 – Treatment with benzarone or benzbromarone can be associated with hepatic injury. Both drugs share structural similarities with amiodarone, a well‐known mitochondrial toxin. Therefore, we investigated the hepatotoxicity of benzarone and benzbromarone as well as the analogues benzofuran and 2‐butylbenzofuran. In isolated rat hepatocytes, amiodarone, benzarone, and benzbromarone (20 μmol/L) decreased mitochondrial membrane potential by 23%, 54% or 81%, respectively.